Company intelligence / Profile preview

Precision Autoimmune Therapeutics

Beijing, Beijing Shi, China

Ownership: Private
Development stage: Other

Overview

CID-103 (anti-CD38 monoclonal antibody) has demonstrated encouraging preclinical efficacy and safety compared to other CD38 antibodies. Clinical development for autoimmune indications is ongoing, enabled by recent financing and a sublicense from CASI. The original multiple myeloma trial in Europe is closed; future development is focused in China. No further disclosed drugs, programs, or technologies were identified under the PAT brand beyond CID-103 for autoimmune diseases.

Therapeutic areas: OncologyHematologyImmunology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

CASI Pharmaceuticals (15% equity stake prior to acquisition, sublicensing of CID-103, later full acquisition)

Beyond the preview

Go deeper on Precision Autoimmune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision Autoimmune Therapeutics.

Explore the full profile